TABLE 1.

Participant demographic characteristics per study part (safety analysis set)

	Part A			Part B			Part C
	Overall n = 56	Placebo n = 14	Enpatorana n = 42	Overall n = 40	Placebo n = 10	Enpatorana n = 30	Enpatoranb n = 8
Sex, n (%)
Male	55 (98.2)	14 (100.0)	41 (97.6)	39 (97.5)	10 (100.0)	29 (96.7)	7 (87.5)
Female	1 (1.8)	0 (0.0)	1 (2.4)	1 (2.5)	0 (0.0)	1 (3.3)	1 (12.5)
Age, y
Meanc ± SD	31 ± 6.8	30 ± 6.5	32 ± 6.9	32 ± 8.0	30 ± 8.4	33 ± 7.9	34 ± 9.3
Minc, max	18, 45	18, 43	20, 45	19, 45	19, 42	21, 45	18, 45
BMId, kg/m2
Meanc ± SD	24.5 ± 2.55	24.4 ± 3.16	24.5 ± 2.35	24.7 ± 2.93	23.5 ± 3.48	25.1 ± 2.68	24.0 ± 2.74
Min, max	18.9, 29.8	18.9, 29.8	19.9, 29.1	19.0, 29.3	19.0, 28.2	20.1, 29.3	18.9, 26.4

Abbreviations: BMI, body mass index; max, maximum; min, minimum; SD, standard deviation.

^a All doses.

^b Participants crossed over from Part A (Cohort 4, 25 mg) to Part C and all received a single 25 mg dose of enpatoran.

^c Arithmetic mean.

^d At screening.